Summary of Key Points
In less than a month, three cases of patient deaths in clinical trials initiated by researchers from Indian Institutes of Technology (IITs) have been exposed in China. All these incidents were first reported by foreign academic/medical media outlets such as *Science*, *Retraction Watch*, STAT, and EndpointsNews*. The most recent case involved the use of an in vivo CAR-T therapy (RXIM002) based on transcriptome biology, which resulted in the death of a patient in their 50s with scleroderma. These incidents have exposed serious issues with the compliance and transparency of IIT trials in China. The IIT model, which was once seen as an advantage for Chinese pharmaceutical companies due to its lower costs and faster progress, is now facing a crisis of trust. Patients may be deterred from participating, international investors may question the reliability of the data, and it could even impact the global expansion of Chinese pharmaceutical firms.
Detailed Analysis
1. The Technical Specificity of this CAR-T Death Case: Different from the Previous Two, but Still Highly Risky
CAR-T therapy essentially involves “arming immune cells with guidance” by modifying T cells in the body to target specific cells. In traditional CAR-T treatments, T cells are removed, modified, and then reinfused into the body. However, in the RXIM002 case, the modification of T cells occurred directly within the body, using a combination of circular RNA and lipid nanoparticles (LNP) as the delivery mechanism. LNP is the same technology used in COVID-19 mRNA vaccines to deliver genetic material into cells. Circular RNA is more stable than regular RNA, allowing T cells to retain the “navigation instructions” for a longer period.
The powerful effects of CAR-T therapy can be both beneficial and harmful: it can rapidly kill target cells (such as tumor cells) but can also trigger a cytokine release syndrome (CRS), where the immune system becomes overactive and releases inflammatory substances that attack the body’s own organs. This is the most common fatal side effect of CAR-T treatments. It is likely that the patient in this case died due to CRS.
Although this case used a different delivery method than the previous two, which involved an AAV virus vector, the risk remains high because CAR-T therapy itself is inherently risky.
2. Issues with the Patient Selection Process: How Did the Patient Meet the Criteria Despite Incompatibility?
The deceased patient was in a state of acute viral infection and myocarditis at the time of enrollment. This is a contraindication for CAR-T therapy, as the immune system is already under stress during an infection, and the added CRS could be too much for the body to handle. The official trial enrollment criteria (available on Clinicaltrial.gov) clearly state that acute infections should be excluded. It is unclear whether the company or hospital failed to properly screen the patient or if the criteria were intentionally relaxed, which is a major source of public outrage.
3. The Mysterious Handling of the Incident: Why Was the Trial Continuing Despite the Death?
The death occurred in March, but the incident was not reported until August. Strangely, the trial status (NCT07322718) still indicates that it is “recruiting participants.” Normally, a fatal outcome in a high-risk phase I trial would lead to an immediate suspension of the investigation. No decision has been made to pause the trial, and no explanation has been provided for this. The company claims that relevant authorities have been informed, but it is unclear which ones (e.g., hospital ethics committees or regulatory agencies) were consulted, nor has it been mentioned whether any adjustments were made to the trial protocol (such as reducing dosages or tightening enrollment requirements).
This lack of transparency raises concerns about whether the trial was rushed and whether risks were deliberately downplayed.
4. The Fatal Impact of These Three Incidents on China’s IIT Model:
The IIT model was once a competitive advantage for Chinese pharmaceutical companies, as it allowed them to conduct trials at lower costs and faster than traditional approaches, enabling them to obtain early data and advance drug development more quickly. Many Chinese biopharmaceutical companies used IITs to gain a head start in the global market. However, these consecutive incidents, especially when reported by foreign media, have severe consequences:
- Destruction of Patient Trust: Who will now dare to participate in IIT trials?
- Doubts from International Investors: Foreign investors may question the authenticity and compliance of Chinese IIT data, affecting financing and international cooperation.
- Hindered Global Expansion: For example, if a trial using domestic IIT data is conducted in the United States and a death occurs, the FDA may review or even halt the trial.
These issues could turn what were once advantages into obstacles. If China’s pharmaceutical industry does not address compliance and transparency concerns, the IIT model may become unsustainable.
Conclusion
These three deaths are not isolated incidents but reflect a concentrated issue of prioritizing speed over compliance in Chinese IIT trials. To preserve the value of the IIT model, patient safety must be top priority. Strict adherence to enrollment criteria, timely disclosure of trial progress, and transparent handling of adverse events are essential. Otherwise, not only will patients suffer, but China’s reputation in the global pharmaceutical community will also be damaged.